ZA200905467B - Method for activation of helper T cell and composition for use in the method - Google Patents

Method for activation of helper T cell and composition for use in the method

Info

Publication number
ZA200905467B
ZA200905467B ZA200905467A ZA200905467A ZA200905467B ZA 200905467 B ZA200905467 B ZA 200905467B ZA 200905467 A ZA200905467 A ZA 200905467A ZA 200905467 A ZA200905467 A ZA 200905467A ZA 200905467 B ZA200905467 B ZA 200905467B
Authority
ZA
South Africa
Prior art keywords
helper
activation
cell
composition
Prior art date
Application number
ZA200905467A
Other languages
English (en)
Inventor
Haruo Sugiyama
Original Assignee
Internat Inst Of Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Internat Inst Of Cancer Immunology Inc filed Critical Internat Inst Of Cancer Immunology Inc
Publication of ZA200905467B publication Critical patent/ZA200905467B/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
ZA200905467A 2007-02-27 2009-08-05 Method for activation of helper T cell and composition for use in the method ZA200905467B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007047317 2007-02-27

Publications (1)

Publication Number Publication Date
ZA200905467B true ZA200905467B (en) 2010-05-26

Family

ID=39721287

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200905467A ZA200905467B (en) 2007-02-27 2009-08-05 Method for activation of helper T cell and composition for use in the method

Country Status (26)

Country Link
US (2) US10139395B2 (sl)
EP (1) EP2119778B1 (sl)
JP (2) JP5225262B2 (sl)
KR (1) KR101598228B1 (sl)
CN (6) CN103103246B (sl)
AU (1) AU2008220031B2 (sl)
BR (1) BRPI0808084A2 (sl)
CA (1) CA2677075C (sl)
CY (1) CY1117150T1 (sl)
DK (1) DK2119778T3 (sl)
ES (1) ES2559062T3 (sl)
HK (1) HK1138321A1 (sl)
HR (1) HRP20160020T1 (sl)
HU (1) HUE027472T2 (sl)
IL (1) IL200161A (sl)
MX (2) MX352947B (sl)
MY (2) MY158219A (sl)
NZ (3) NZ578721A (sl)
PL (1) PL2119778T3 (sl)
PT (1) PT2119778E (sl)
RU (2) RU2009135802A (sl)
SG (1) SG177998A1 (sl)
SI (1) SI2119778T1 (sl)
UA (1) UA101608C2 (sl)
WO (1) WO2008105462A1 (sl)
ZA (1) ZA200905467B (sl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2378264T3 (es) 2003-11-05 2012-04-10 International Institute Of Cancer Immunology, Inc. Péptido antigénico de unión a HLA-DR derivado de WT1
EP1951281B1 (en) 2005-10-17 2015-04-15 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
EP3117836A1 (en) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and uses thereof
CN103103246B (zh) 2007-02-27 2018-05-01 株式会社癌免疫研究所 活化辅助t细胞的方法以及用于该方法的组合物
AR076349A1 (es) * 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
EP2698430A3 (en) * 2009-12-08 2014-03-05 Wilson Wolf Manufacturing Corporation Methods of cell culture for adoptive cell therapy
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
WO2012046730A1 (ja) * 2010-10-05 2012-04-12 国立大学法人大阪大学 ヘルパーｔ細胞の活性化方法
BR112014002747A2 (pt) * 2011-09-14 2020-10-27 International Institute Of Cancer Immunology, Inc método para medir um anticorpo anti-wt1
CN104136609B (zh) * 2011-12-14 2016-12-07 国立大学法人高知大学 辅助性t细胞诱导多肽的修饰
CN104684577B (zh) 2012-01-13 2018-05-08 纪念斯隆凯特林癌症中心 免疫原性wt-1肽及其使用方法
KR20150046346A (ko) * 2012-09-12 2015-04-29 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 항원 특이적 헬퍼 t 세포 리셉터 유전자
EP2933261B1 (en) 2012-12-17 2020-06-10 Otsuka Pharmaceutical Co., Ltd. Method for activating helper t cell
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
PT2945647T (pt) 2013-01-15 2020-11-26 Memorial Sloan Kettering Cancer Center Péptidos imunogénicos wt-1 e métodos de uso dos mesmos
WO2015129790A1 (ja) * 2014-02-26 2015-09-03 株式会社バイオイミュランス Ｗｔ１抗原性ポリペプチド、及び該ポリペプチドを含む抗腫瘍剤
US10695385B2 (en) 2015-06-25 2020-06-30 National University Corporation Kobe University Oral cancer vaccine
CN110214028A (zh) 2016-12-26 2019-09-06 国立大学法人神户大学 联合使用口服肿瘤疫苗和免疫抑制阻滞剂的癌症治疗
CA3162690A1 (en) 2019-12-31 2021-07-08 Minoru S. H. Ko Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
KR102647825B1 (ko) * 2021-07-22 2024-03-14 서울대학교산학협력단 항-hla-dp 단클론 항체 및 이의 용도

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726288A (en) 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
BRPI9912663B8 (pt) 1998-07-31 2021-07-06 Int Inst Cancer Immunology Inc vacina contra cáncer e polipeptìdeo.
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
MY139226A (en) 1998-09-30 2009-08-28 Corixa Corp Compositions and methods for wt1 specific immunotherapy
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
AU2001247220A1 (en) 2000-02-22 2001-09-03 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
TWI318630B (en) 2001-03-22 2009-12-21 Int Inst Cancer Immunology Inc Wt1 modified peptide
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
DE60238958D1 (de) 2001-06-29 2011-02-24 Chugai Pharmaceutical Co Ltd Krebsimpfstoff mit einem Krebs-Antigen auf Grundlage des Produkts aus dem Tumorunterdrückungsgen WT1 und einem kationischen Liposom
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
EP1447091A4 (en) 2001-09-28 2008-02-13 Institute Of Can International NEW METHOD FOR INDUCTION OF ANTIGEN SPECIFIC T CELLS
US20050002951A1 (en) 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
CN101113163B (zh) * 2002-06-12 2010-10-06 株式会社国际癌症免疫研究所 Hla-a24限制性癌抗原肽
WO2004024175A1 (ja) 2002-09-12 2004-03-25 Haruo Sugiyama 癌抗原ペプチド製剤
ATE442378T1 (de) 2002-09-20 2009-09-15 Int Inst Cancer Immunology Inc Substituierte wt1-peptide
US20060217297A1 (en) 2003-01-15 2006-09-28 Haruo Sugiyama Dimerized peptide
KR101431312B1 (ko) 2003-06-27 2014-08-20 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ1 백신 적응 환자의 선택 방법
ES2378264T3 (es) * 2003-11-05 2012-04-10 International Institute Of Cancer Immunology, Inc. Péptido antigénico de unión a HLA-DR derivado de WT1
US7488718B2 (en) * 2003-12-01 2009-02-10 Sloan Kettering Institue For Cancer Research Synthetic HLA binding peptide analogues and uses thereof
ATE462003T1 (de) 2004-03-31 2010-04-15 Int Inst Cancer Immunology Inc Aus wt1 stammende krebsantigenpeptide
JP4719876B2 (ja) 2005-04-04 2011-07-06 国立大学法人愛媛大学 Ｈｌａクラスｉｉ拘束性ｗｔ１抗原ペプチド
EP1951281B1 (en) 2005-10-17 2015-04-15 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
KR101385805B1 (ko) 2005-11-30 2014-04-16 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 신규 펩티드 화합물
PL1988163T3 (pl) 2006-02-22 2012-11-30 Int Inst Cancer Immunology Inc Ograniczony do hla-a*3303 peptyd wt1 i zawierająca go kompozycja farmaceutyczna
EP3117836A1 (en) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and uses thereof
DK2341142T3 (en) 2006-12-28 2014-12-08 Int Inst Cancer Immunology Inc HLA-A * 1101-restricted WT1 peptide or pharmaceutical composition comprising this
CN103103246B (zh) 2007-02-27 2018-05-01 株式会社癌免疫研究所 活化辅助t细胞的方法以及用于该方法的组合物
EP2116596A4 (en) 2007-03-05 2010-04-07 Int Inst Cancer Immunology Inc L-CELL RECEPTOR GENE SPECIFIC TO A CANCER ANTIGEN, PEPTIDE CODED BY THE GENE AND THEIR USE
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
WO2012046730A1 (ja) 2010-10-05 2012-04-12 国立大学法人大阪大学 ヘルパーｔ細胞の活性化方法
EP2933261B1 (en) 2012-12-17 2020-06-10 Otsuka Pharmaceutical Co., Ltd. Method for activating helper t cell

Also Published As

Publication number Publication date
NZ578721A (en) 2012-04-27
CN103149366A (zh) 2013-06-12
EP2119778A4 (en) 2010-08-18
PT2119778E (pt) 2016-02-15
MY158219A (en) 2016-09-15
DK2119778T3 (en) 2016-01-25
NZ599161A (en) 2012-07-27
CN103103246B (zh) 2018-05-01
CN104312974B (zh) 2018-09-04
JPWO2008105462A1 (ja) 2010-06-03
AU2008220031B2 (en) 2013-06-13
CN103103246A (zh) 2013-05-15
MX352947B (es) 2017-12-14
EP2119778B1 (en) 2015-11-04
CY1117150T1 (el) 2017-04-05
MY164867A (en) 2018-01-30
CA2677075A1 (en) 2008-09-04
EP2119778A1 (en) 2009-11-18
HUE027472T2 (en) 2016-09-28
CN101622344A (zh) 2010-01-06
JP5225262B2 (ja) 2013-07-03
UA101608C2 (uk) 2013-04-25
PL2119778T3 (pl) 2016-04-29
US10139395B2 (en) 2018-11-27
US20200064332A1 (en) 2020-02-27
RU2680539C2 (ru) 2019-02-22
CN104774910A (zh) 2015-07-15
BRPI0808084A2 (pt) 2014-07-22
US20100247556A1 (en) 2010-09-30
CN104774910B (zh) 2018-04-10
US11555814B2 (en) 2023-01-17
SI2119778T1 (sl) 2016-03-31
IL200161A (en) 2015-11-30
HK1138321A1 (en) 2010-08-20
CN104312974A (zh) 2015-01-28
KR101598228B1 (ko) 2016-02-26
MX2009009168A (es) 2009-09-07
SG177998A1 (en) 2012-02-28
WO2008105462A1 (ja) 2008-09-04
JP5714619B2 (ja) 2015-05-07
NZ599160A (en) 2012-07-27
IL200161A0 (en) 2011-08-01
CN103088103A (zh) 2013-05-08
CA2677075C (en) 2018-07-10
RU2014104572A (ru) 2015-08-20
RU2009135802A (ru) 2011-04-10
ES2559062T3 (es) 2016-02-10
HRP20160020T1 (hr) 2016-02-12
JP2013139448A (ja) 2013-07-18
KR20090125067A (ko) 2009-12-03
CN103149366B (zh) 2018-06-15
CN103088103B (zh) 2015-09-30
AU2008220031A1 (en) 2008-09-04

Similar Documents

Publication Publication Date Title
IL200161A0 (en) Method for activation of helper t cell and composition for use in the method
IL267138A (en) Improved composition of cells and methods for its preparation
GB2443823B (en) Devices and methods for use in construction
SG10201605686XA (en) Polishing Composition And Polishing Method Using The Same
IL202329A0 (en) Methods and compositions for stimulating cells
EP2180933A4 (en) POROUS BODIES AND METHODS
ZA200905886B (en) Methods and kits for administering probiotics
EP2189519A4 (en) CELL CULTURE INSTRUMENT AND CELL CUKLTURE PROCESS WITH THIS
HK1147254A1 (en) 5-anilinoimidazopyridines and methods of use 5-
EP2129429A4 (en) ANCHORING APPARATUS AND METHODS OF USE
EP2308884A4 (en) PROCESS FOR THE PREPARATION OF HETEROSUBSTITUTED ALKYLHALOHYDROSILANE AND ITS USE
GB0605702D0 (en) Materials and methods for immune cell stimulation
EP2324956A4 (en) POLISHING COMPOSITION AND THIS USE POLISHING METHOD
GB0709781D0 (en) Composition and method
GB0724967D0 (en) Composition and method
GB0905971D0 (en) Antitussive composition and method for making the same
GB0620930D0 (en) Composition and method for use thereof
ZA201004894B (en) Nuctraceutical composition and methods of use
EP2115127A4 (en) METHOD AND COMPOSITIONS FOR IMPROVING CELL HEALTH IN CULTURES
ZA201004893B (en) Nuctraceutical composition and methods of use
ZA201008261B (en) Non-hydrating plaster composition and method
MY152929A (en) Polishing composition and polishing method
EP2348865A4 (en) BETA-HYDROXY-GAMMA-AMINOPHOSPHONATES, THEIR METHODS OF PREPARATION AND THEIR USE
EP2185685A4 (en) NEW PROCESSES AND NEW CELL LINES
TWI365216B (en) Polishing composition for polishing lithium aluminate and method of using the same